Stemline Therapeutics (STML) Tops Q1 EPS by 8c

Stemline Therapeutics (NASDAQ: STML) reported Q1 EPS of ($0.51), $0.08 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $205.65 million, versus $121.43 million reported last year.

For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
• InspireMD (NSPR) Tops Q2 EPS by 1c